Drugmakers Allergan (AGN) and Novo Nordisk (NVO) reported third-quarter earnings that topped expectations with Novo Nordisk also beating on sales though Allergan’s revenue was just in line.

XAutoplay: On | OffAllergan reported adjusted income of $4.15 per share on sales of $4.03 billion for the third quarter, compared with $3.32 a share and $3.62 billion, respectively. Analysts polled by Zacks Investment Research had called for adjusted profit of $4.06 a share on $4.03 billion in sales.

Novo Nordisk reported adjusted profit of 63 cents per American Depository Receipt on $4.198 billion in sales, compared with a respective 58 cents and $4.13 billion in the year-ago period. Analysts had modeled adjusted income of 58 cents per ADR on $4.03 billion in revenue.

In premarket trading on the stock market today, Allergan lifted 1.%, near 177.20. Novo Nordisk sank 2.2%, near 48.70.

RELATED:

Mylan Topples As President Named In ‘Mind-Blowing’ Antitrust Scheme

How Allergan’s ‘Public Relations Backlash’ Deepened This Week

Allergan Tanks After Judge Invalidates Restasis Patents